聚胺-蛋白质结合:治疗性蛋白质输送的新范式
Xiao Zhang1, Shiwei Fu1, Bowen Zhao1
1Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
概括
聚胺-蛋白质结合通过提高稳定性和生物可用性来增强治疗性蛋白质的输送. 这一创新策略解决了诸如短半衰期和免疫性等局限性,以更好地治疗疾病.
科学领域:
- 生物材料科学 生物材料科学
- 药物运输 药物运输 药物运输
- 蛋白质工程是指蛋白质工程.
背景情况:
- 蛋白质疗法提供有针对性的疾病治疗,但面临的挑战包括稳定性差,循环半衰期短,免疫性和高成本.
- 可生物降解和生物相容的多材料为克服这些治疗蛋白质限制提供了新的解决方案.
研究的目的:
- 审查聚蛋白-蛋白质结合的最新进展,以改善治疗性蛋白质的输送.
- 讨论设计原则,施工方法和这些结合物的应用.
主要方法:
- 概括了聚合成和蛋白质修饰技术的创新.
- 突出了生物对等反应的使用,以实现精确的结合.
- 审查合物净化和表征的方法.
主要成果:
- 聚胺-蛋白质结合体显示了治疗蛋白质的增强稳定性,可溶性和生物可用性.
- 这些结合物提高治疗效果,减少不良副作用.
- 在临床前和临床环境中,各种多蛋白合物已经显示出有前途的结果.
结论:
- 聚胺-蛋白质结合是一种强大的策略,可以增强治疗性蛋白质的输送并克服临床挑战.
- 在合成,结合和表征方面的持续研究将进一步推进这一领域.
- 这种方法对未来的药物开发和改善患者治疗结果具有重大潜力.
相关概念视频
Conjugated Proteins
18.2K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.2K
Phase II Conjugation Reactions: Overview
173
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
173
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Tagging and Fusion Proteins
6.6K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.6K
Protein-Drug Binding: Mechanism and Kinetics
357
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
357
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K


